company logo

Sr Director/ Director, Translational Science (Biomarker Lead) at Allogene Therapeutics in South San Francisco, CA



$200K — $250K *


Life Sciences


5 - 7 years

Job Description

See More

Valid through: 3/10/2021

About Allogene Therapeutics

Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors. The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer. Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director. On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. The deal will add the promising CAR-T candidate to Gilead's existing portfolio. The acquisition was completed in October 2017. In October 2017, Kite Pharma’s therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. MIT Technology Review ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017.
stats icon
Total Jobs:
stats icon
Average Pay:
stats icon
Total value of jobs:
Learn More About Allogene Therapeutics view all icon
* Ladders Estimates

More Jobs at Allogene Therapeutics

Similar Jobs

More Pharmaceuticals & Biotech Jobs

Field Service Engineer

Confidential Company

Boston, MA 02110

5 days ago

Find similar Senior Director jobs: